Among the great hopes of 21st century medical science is that the Precision Medicine Initiative (PMI) will help doctors and patients avoid ineffective treatment regimes. A government panel recently published a report on the million-person cohort needed to make the PMI program a reality.
The president's choice for the next head of the FDA is Robert Califf, a cardiologist who has overseen several clinical trial initiatives at Duke University and founded both the Duke University Clinical Research Institute and the Duke Translational Medicine Institute.